Saudi: Tabuk partners with Levolta to commercialise OA therapy

Saudi: Tabuk partners with Levolta to commercialise OA therapy

Saudi Arabia - Tabuk Pharmaceutical Manufacturing Company has signed an exclusive licence and distribution agreement with US’ Levolta Pharmaceuticals to commercialise an investigational osteoarthritis (OA) therapy in Middle East and Africa.

VOLT01 is a patented, novel combination drug that has shown promise in Phase II and Phase IIb/III clinical trials for treating OA, which currently has no cure.

Mohammed Al Hagbani, CEO of Tabuk Pharmaceuticals and President of Astra Industrial Group, said: "We are confident that VOLT01 will play a major role in improving the health conditions of over 5 million osteoarthritis patients in Saudi Arabia and many other patients across the region suffering from this disease. Our partnership with Levolta strengthens our commitment to further support the kingdom's 2030 vision by providing unique medications addressing different therapy areas.”

Market authorisation

Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation and will be responsible for registering, importing, and commercialising VOLT01 in the MEA region.

“We are excited to announce this partnership with Tabuk Pharmaceuticals, as it represents the next step in bringing the first disease-modifying therapy for osteoarthritis to market,” said Levolta Chief Executive Officer (CEO), Richard P Becker, Jr. “Our goal is to fill the global void in the treatment